GlassScriptPhysician profile
James A Richardson
NPI 1467454736
$8,446.84
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,832 · 2020: $1,461 · 2021: $1,865 · 2022: $1,467 · 2023: $1,550 · 2024: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,662 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.78 |
| Education | $159.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,338.51 | 2019-2024 | Leqvio |
| Amgen INC. | $1,205.32 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $909.61 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $599.41 | 2021-2024 | Verquvo |
| Astellas Pharma US INC | $486.74 | 2019-2023 | Cresemba |
| Esperion Therapeutics, INC. | $472.33 | 2020-2023 | Nexletol |
| Amarin Pharma, INC. | $448.83 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $374.83 | 2019-2023 | Camzyos, Eliquis |
| Pfizer INC. | $318.67 | 2019-2023 | |
| Abbott Laboratories | $279.91 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $261.38 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $256.70 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.51 | 2019-2023 | Jardiance |
| Tactile Systems Technology INC | $202.19 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Kowa Pharmaceuticals America, INC. | $163.76 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $153.47 | 2019 | |
| Inspire Medical Systems, INC. | $109.30 | 2023-2024 | Inspire |
| Biotronik INC. | $99.62 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $88.84 | 2021-2023 | Arcalyst |
| Allergan, INC. | $75.69 | 2020 | |
| Medtronic, INC. | $61.89 | 2021 | |
| Impulse Dynamics (USA) INC. | $48.85 | 2023 | Optimizer |
| Cvrx, INC. | $44.04 | 2022 | |
| Chiesi USA, INC. | $43.96 | 2019 | |
| Edwards Lifesciences Corporation | $39.75 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $37.31 | 2023 | Inpefa |
| Atricure, INC. | $22.62 | 2022 | |
| Bardy Diagnostics, INC. | $20.00 | 2019 | |
| Viiv Healthcare Company | $19.16 | 2024 | Apretude |
| Cardinal Health 200 LLC | $18.51 | 2020 | |
| Angiodynamics, INC. | $12.80 | 2022 | |
| Cook Medical LLC | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.